drugset / Trial / NCT02350725

Furosemide Pharmacodynamics and Pharmacokinetics After Subcutaneous or Oral Administration

NCT02350725

Phase 1/2 Completed 10 enrolled scPharmaceuticals, Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this pilot study is to investigate the pharmacodynamic and pharmacokinetic parameters of a novel furosemide formulation administered subcutaneously as compared to oral furosemide.

Timeline

Start
2014-12
Primary completion
2015-06
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Furosemide Other / unclassified 80 mg Subcutaneous

Indications